Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Antibody persistence after DTaP-IPV-HB-Hib or Infanrix hexa vaccination in Latin American children
2011-004451-39Phase 3
- Sponsor
- Sanofi
- Start
- Apr 2016
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3 trial of DTaP-IPV-Hep B-PRP-T vaccine and pertussis filamentous haemagglutinin in diphtheria, Tetanus, pertussis and 3 more (2 arms), sponsored by Sanofi. Primary endpoints: Antibody persistence at 3.5 years of age and Antibody persistence at 4.5 years of age.
02
Drugs
DTaP-IPV-Hep B-PRP-T vaccinepertussis filamentous haemagglutinin
03
Conditions
diphtheriaTetanuspertussishepatitis B (HBV)poliomyelitis
Beyond the preview
Go deeper on 2011-004451-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004451-39.